Evidence map›Paper›PMID 26194320›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2015

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Michael W Weiner, Dallas P Veitch, Paul S Aisen, Laurel A Beckett, Nigel J Cairns, Jesse Cedarbaum, Michael C Donohue, Robert C Green, Danielle Harvey, Clifford R Jack and 9 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 2 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 2 syntheses or guidelines pooled it, 241 citations in OpenAlex.

  1. Interpretable machine learning for dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. A seven-year longitudinal study of the Alzheimer's disease blood metabolome.medRxiv : the preprint server for health sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  17. Review
  18. Article
  19. The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  20. The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 2 countries.

Michael W WeinerDepartment of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
Dallas P VeitchDepartment of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
Paul S AisenDepartment of Neurosciences, University of California- San Diego, La Jolla, CA, USA.
Laurel A BeckettDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
Nigel J CairnsDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Jesse CedarbaumNeurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA.
Michael C DonohueDivision of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, San Diego, CA, USA.
Robert C GreenDivision of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Danielle HarveyDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
William JagustHelen Wills Neuroscience Institute and the School of Public Health, University of California Berkeley, Berkeley, CA, USA.
John C MorrisDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Andrew J SaykinDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Leslie ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Paul M ThompsonImaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Marina Del Rey, CA, USA.
Arthur W TogaLaboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California Los Angeles, CA, USA.
John Q TrojanowskiDepartment of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alzheimer's Disease Neuroimaging Initiative
Mayo Clinic in Arizona · USUniversity of California, Davis · USUniversity of California San Diego · USAlzheimer’s Disease Neuroimaging Initiative · USBiogen (United States) · USHarvard University · USIndiana University – Purdue University Indianapolis · USInstitute on Aging · USMarina Del Rey Hospital · USSan Francisco VA Medical Center · USUniversity of California, Berkeley · USUniversity of California, San Francisco · USUniversity of Pennsylvania · USUniversity of Southern California · USWashington University in St. Louis · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
TR&D3: Intrinsic Surface MappingP41EB015922 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VAN HORN, JOHN DARRELL · 2012 to 2022
$14.1M
Alzheimer's disease risk analyzed using population imaging genomicsR01AG040060 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2011 to 2016
$2.5M
NCATS NIH HHS UL1 TR001108NIA NIH HHS 5U01AG024904-10NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010129NIA NIH HHS R01 AG040060NIA NIH HHS U01 AG024904NIBIB NIH HHS P41 EB015922
6 · The paper itself

Abstract

introductionThe Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials.

methodsWe searched for ADNI publications using established methods.

resultsADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. DISCUSSION: ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

Indexed as

Alzheimer DiseaseBiomarkersClinical Trials as TopicDatabases, BibliographicDisease ProgressionHumansLongitudinal StudiesNeuroimagingBiomarkersAD biomarker signatureAlzheimer's diseaseAmyloid phenotypingClinical trial biomarkersData-sharingTau imagingWorldwide ADNI

Identifiers

PMID26194320
PMCPMC4659407
OpenAlexW1858759550

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.